These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25971532)

  • 1. Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.
    Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Knox JJ; McNamara MG; Jitlal M; Wasan H; Bridgewater J; Valle JW; Mau-Sorensen M
    Eur J Cancer; 2015 Jul; 51(11):1381-8. PubMed ID: 25971532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Sasaki H; Sueda T
    J Surg Oncol; 2014 Sep; 110(4):422-9. PubMed ID: 24889968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum tumor markers in bile duct cancer--a review.
    Grunnet M; Mau-Sørensen M
    Biomarkers; 2014 Sep; 19(6):437-43. PubMed ID: 24857368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis.
    Petersen-Benz C; Stiehl A
    Z Gastroenterol; 2005 Jun; 43(6):587-90. PubMed ID: 15986288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
    Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Takahara N; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1291-7. PubMed ID: 24121456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA19-9 as a predictor of resectability in patients with borderline resectable pancreatic cancer.
    He Z; Lu H; Du X; Hu W; Zhaoda BT
    Hepatogastroenterology; 2013 Jun; 60(124):900-3. PubMed ID: 23321027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.
    Bergquist JR; Ivanics T; Storlie CB; Groeschl RT; Tee MC; Habermann EB; Smoot RL; Kendrick ML; Farnell MB; Roberts LR; Gores GJ; Nagorney DM; Truty MJ
    J Surg Oncol; 2016 Sep; 114(4):475-82. PubMed ID: 27439662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.
    Wang RF; Song BR; Peng JJ; Cai GX; Liu FQ; Wang MH; Cai SJ; Ye X
    Hepatogastroenterology; 2014 Jun; 61(132):994-9. PubMed ID: 26158155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative chemoradiotherapy for extrahepatic bile duct cancer.
    Park JH; Choi EK; Ahn SD; Lee SW; Song SY; Yoon SM; Kim YS; Lee YS; Lee SG; Hwang S; Lee YJ; Park KM; Kim TW; Chang HM; Lee JL; Kim JH
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):696-704. PubMed ID: 20510541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer.
    Kawamata H; Yamashita K; Nakamura K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Kumamoto Y; Watanabe M
    Anticancer Res; 2013 Feb; 33(2):583-94. PubMed ID: 23393352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.